SCHEMBL2891980

SCHEMBL2891980

O=C1c2c(O)c(=O)n(Cc3nccc4ccccc34)c(=O)n2CCN1Cc1ccc(F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.41
GRM2 Q14416 1/20 0.41
HCRTR1 O43613 1/20 0.39
HCRTR2 O43614 1/20 0.39
ALDH1A1 P00352 3/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TP53 P04637 2/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
TSHR P16473 1/20 0.38
HTT P42858 1/20 0.38
HSD17B10 Q99714 1/20 0.38
SCD O00767 2/20 0.38
PKM P14618 2/20 0.38
NPSR1 Q6W5P4 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
DPP4 P27487 3/20 0.37
MAPT P10636 1/20 0.37
AKR1B1 P15121 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4145906 0.77 TACR1 (0.47) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2899665 0.76 KCNH2 (0.41) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2892046 0.76 KCNH2 (0.40) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2891898 0.75 KCNH2 (0.42) KCNH2GRM2ALDH1A1TP53AKR1B1
SCHEMBL2898490 0.74 KCNH2 (0.41) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2890924 0.72 KCNH2 (0.45) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2898603 0.72 DRD4 (0.41) KCNH2GRM2ALDH1A1LMNASMN1; SMN2
SCHEMBL2892150 0.72 CYP19A1 (0.45) KCNH2GRM2ALDH1A1TP53KDM4E
SCHEMBL2898063 0.71 ALDH1A1 (0.42) KCNH2GRM2ALDH1A1KDM4EHPGD
SCHEMBL2895253 0.71 KCNH2 (0.39) KCNH2GRM2ALDH1A1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US claimed
EP-1725102-A4 HIV INTEGRASE INHIBITORS MERCK & CO INC (US) 2009-04-29 EP claimed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US claimed
EP-1725102-A1 HIV INTEGRASE INHIBITORS Merck & Co., Inc. (US) 2006-11-29 EP claimed
WO-2005092099-A1 HIV INTEGRASE INHIBITORS MERCK & CO., INC. (US) 2005-10-06 WO claimed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-7820680-B2 HIV integrase inhibitors MERCK & CO., INC. (US) 2010-10-26 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed
US-20080009490-A1 Hiv Integrase Inhibitors MERCK SHARP & DOHME CORP. 2008-01-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009490-A1 Hiv Integrase Inhibitors TYMS, UNG, TYMP KCNH2 3441/4885GRM2 4668/4885HCRTR1 3976/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.